GBA Presents: RADIO SAVANT-!

stonedinvestor said:
stonedinvestor said:
--UPDATE--

RADIO SAVANT PORTFOLIO- GBA Buys- :caution:

1- SIGA * (new)- $12.60

2- Coca Cola- $61.00--> $59---> $62.87

3- Nutrian- $84.25--------> $87---->$83! ---->$80<-------- :mad:

4- FORMULA 1-- $55.85 FWONA---> $57.81

5- Boston Scientific $36.10---> $37.94

6- Next Era ENERGY - $76.50 (VAN)---> $78.00

(Plus 2 buys yesterday)
 
I am looking for a total of 11 names. Everyone help out! Lets go!

NEXI vs NEXI

Nexi initiated with an Outperform at Credit Suisse 05:05 NEXXY Credit Suisse analyst Justin Forsythe initiated coverage of Nexi with an Outperform rating and EUR 10.50 price target. The company is well positioned to grow market share in Italy and Nordic countries as well as expand its exposure to fast-growth regions such as Poland, Forsythe tells investors in a research note.

Neximmune assumed with an Overweight at Cantor Fitzgerald 07:41 NEXI
 
stonedinvestor said:
Idea- FIGS

Figs initiated with a Strong Buy at Raymond James 16:54 FIGS Raymond James analyst Rick Patel initiated coverage of Figs with a Strong Buy rating and $15 price target as part of a broader sector note initiating coverage of Digital Commerce. The company has created a "better mousetrap" in the $12B U.S. Healthcare apparel market, the analyst tells investors in a research note, adding that he also sees it as an attractive market segment as jobs in the U.S. Healthcare market are poised to grow 15% from 2019-2029. Patel further notes that he sees the potential for FIGS to stretch beyond its core scrub assortment with total addressable market expansion via lifestyle product, industries outside of Healthcare, and International expansion.

Huge amount of healthcare workers in the system coming up. As needed! They need funky scrubs!

FIGS-$8.30
More...
FIGS is $8.60 on the ask.
Are you saying buy it there?
 
Imax extends current share-repurchase program through June 30, 2023 07:32 IMAX

Bunge upgraded to Buy from Neutral at BofA

BG-$91<------------

Constellation Brands CEO 'pleased' with 'strong start' to fiscal year 07:11 STZ, STZ.B "We're pleased with our strong start to the fiscal year. Across the business we're driving consumer demand for our exceptional portfolio of premium, high-end products while executing strong financial and operational performance," said CEO Bill Newlands.

STZ-$243 <--------------

William Blair upgrades ShotSpotter with 60% upside over two years 07:04 SSTI William Blair analyst Matthew Pfau upgraded ShotSpotter to Outperform from Market Perform without a price target. Since the downgrade to Market Perform in August of 2019, the business has increased revenue by 66% while the stock is down 24%, Pfau tells investors in a research note. In addition to a lower valuation, the funding environment has improved and is "better than it ever has been" in ShotSpotter's public life, and management has better visibility into the business driven by less reliance on Respond deals to tier-one cities, longer- term contracts, and product diversification, Pfau contends. The analyst believes ShotSpotter should be less impacted by a recession than many other software-as-a-service businesses. Violent crime is increasing in many cities across the United States, and ShotSpotter is one of only a few tools cities can implement to reduce gun violence, he contends. The analyst sees greater than 60% upside to shares over the next two years.

SSTI-$25.50 <------------
 
vanzandt said:
poww $4.27 now
You better bail out Stoney.
It's gonna drop.
More...



We sold half on the pop yesterday AH + 11% -- House money now we are holding!>


In general folks you want to hide in low priced names now as indexes purge and the news from Softbank ripples thru the market.

POWW is a perfect example.
 
RH price target lowered to $274 from $315 at Wedbush 07:46 RH Wedbush analyst Seth Basham lowered the firm's price target on RH to $274 from $315 and keeps an Outperform rating on the shares. The analyst notes RH revised its outlook for full year 2022, now expecting a 2%-5% sales decline versus the prior guidance calling for sales flat to up 2% year-over-year, based on lower-than-expected demand almost 2/3 of the way through Q2 and less than one month since last guiding the year lower. Further, the softening trends RH is currently seeing in the business and the "deteriorating macro-economic environment" lead the company to now expect weakening demand throughout the rest of the year, Basham adds.
 
You must log in or register to reply here.
Back
Top